Cargando…

Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?

BACKGROUND: The risk of pre-term birth (PTB) associated with the use of protease inhibitors (PIs) during pregnancy remains a subject of debate. Recent data suggest that ritonavir boosting of PIs may play a specific role in the initiation of PTB, through an effect on the maternal–fetal adrenal axis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakkar, Fatima, Boucoiran, Isabelle, Lamarre, Valerie, Ducruet, Thierry, Amre, Devendra, Soudeyns, Hugo, Lapointe, Normand, Boucher, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458515/ https://www.ncbi.nlm.nih.gov/pubmed/26051165 http://dx.doi.org/10.7448/IAS.18.1.19933

Ejemplares similares

Impact of maternal HIV-1 viremia on lymphocyte subsets among HIV-exposed uninfected infants: protective mechanism or immunodeficiency
por: Kakkar, Fatima, et al.
Publicado: (2014)

No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study
por: Djeha, Ameyo, et al.
Publicado: (2019)

1614 High Rates of Preterm Birth and Small for Gestational Age in a Cohort of HIV Infected Women in Canada: Role of Ritonavir Boosted Regimens?
por: Kakkar, Fatima, et al.
Publicado: (2014)

Health outcomes and the transition experience of HIV-infected adolescents after transfer to adult care in Québec, Canada
por: Kakkar, Fatima, et al.
Publicado: (2016)

115. Results of a Targeted Neonatal Screening Program for Congenital Cytomegalovirus Infection in Montreal, Quebec
por: Renaud, Christian, et al.
Publicado: (2018)

Identifying Clinical Criteria for an Expanded Targeted Approach to Screening for Congenital Cytomegalovirus Infection—A Retrospective Study
por: Akiva, Maya Heled, et al.
Publicado: (2023)

Leukocyte Telomere Length in HIV-Infected and HIV-Exposed Uninfected Children: Shorter Telomeres with Uncontrolled HIV Viremia
por: Côté, Hélène C. F., et al.
Publicado: (2012)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy
por: Carvalho, Sabrina, et al.
Publicado: (2022)

Safety of combination antiretroviral prophylaxis in high-risk HIV-exposed newborns: a retrospective review of the Canadian experience
por: Kakkar, Fatima W, et al.
Publicado: (2016)

HIV-1 Genetic Diversity in Antenatal Cohort, Canada
por: Akouamba, Bertine S., et al.
Publicado: (2005)

Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada
por: Quesnel-Vallières, Mathieu, et al.
Publicado: (2011)

Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis
por: Bierman, WFW, et al.
Publicado: (2010)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Chitinase-3-like Protein 1 Is Associated with Poor Virologic Control and Immune Activation in Children Living with HIV
por: Bernard, Isabelle, et al.
Publicado: (2022)

Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in Montreal, Canada
por: Wizman, Sarah, et al.
Publicado: (2016)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Hepatocyte Nuclear Factor 4 Alpha Polymorphisms and the Metabolic Syndrome in French-Canadian Youth
por: Marcil, Valérie, et al.
Publicado: (2015)

Head Ultrasound or MRI? The Role of Neuroimaging in the Assessment of Symptomatic and Asymptomatic Infants with Congenital CMV Infection
por: Smiljkovic, Mina, et al.
Publicado: (2017)

Head ultrasound, CT or MRI? The choice of neuroimaging in the assessment of infants with congenital cytomegalovirus infection
por: Smiljkovic, Mina, et al.
Publicado: (2019)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes
por: Boucoiran, I, et al.
Publicado: (2015)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

SARS-CoV-2 vaccine uptake and reasons for hesitancy among Canadian pregnant people: a prospective cohort study
por: Gorgui, Jessica, et al.
Publicado: (2022)

Effect of maternal age on the risk of preterm birth: A large cohort study
por: Fuchs, Florent, et al.
Publicado: (2018)

999 The Role of Quantitative Blood PCR in the Management of Congenital Cytomegalovirus Infection
por: Leduc, Dorothée, et al.
Publicado: (2014)

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR
por: Wyatt, Christina M., et al.
Publicado: (2020)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_taca7enb3hbg4bt4mhrppogksn